Usefulness and safety of Omalizumab (anti-IgE monoclonal antibody) on oral immunotherapy for patients with severe food allergy

Usefulness and safety of Omalizumab (anti-IgE monoclonal antibody) on oral immunotherapy for patients with severe food allergy - Usefulness and safety of Omalizumab (anti-IgE monoclonal antibody) on oral immunotherapy for patients with severe food allergy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008688

Enrollment

Registered

2012-09-01

Start date

2012-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Food allergy

Interventions

Omalizumab

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.More than 5 years old 2.Food allergy with hen's egg,cow milk, wheat and peanuts 3.Written Informed Consent

Exclusion criteria

Exclusion criteria: Decision of ineligibility by a physician.

Design outcomes

Primary

Measure	Time frame
Analysis of liquidity factors	—

Countries

Japan

Contacts

Public ContactShoichiro Taniuchi

Kansai Medical University Department of Pediatrics

taniuchi@takii.kmu.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026